![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BEX4 |
Gene summary for BEX4 |
![]() |
Gene information | Species | Human | Gene symbol | BEX4 | Gene ID | 56271 |
Gene name | brain expressed X-linked 4 | |
Gene Alias | BEXL1 | |
Cytomap | Xq22.1 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9NWD9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56271 | BEX4 | ATC13 | Human | Thyroid | ATC | 1.82e-20 | 2.67e-01 | 0.34 |
56271 | BEX4 | ATC1 | Human | Thyroid | ATC | 1.38e-03 | -2.32e-01 | 0.2878 |
56271 | BEX4 | ATC4 | Human | Thyroid | ATC | 3.76e-08 | 4.55e-01 | 0.34 |
56271 | BEX4 | ATC5 | Human | Thyroid | ATC | 2.59e-18 | 3.11e-01 | 0.34 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070593 | Esophagus | HGIN | chromosome segregation | 71/2587 | 346/18723 | 3.47e-04 | 5.62e-03 | 71 |
GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
GO:00356015 | Esophagus | ESCC | protein deacylation | 79/8552 | 112/18723 | 8.30e-08 | 1.42e-06 | 79 |
GO:00987325 | Esophagus | ESCC | macromolecule deacylation | 80/8552 | 116/18723 | 3.19e-07 | 4.50e-06 | 80 |
GO:00064765 | Esophagus | ESCC | protein deacetylation | 70/8552 | 101/18723 | 1.29e-06 | 1.58e-05 | 70 |
GO:00903114 | Esophagus | ESCC | regulation of protein deacetylation | 30/8552 | 48/18723 | 1.40e-02 | 4.57e-02 | 30 |
GO:00070592 | Oral cavity | OSCC | chromosome segregation | 206/7305 | 346/18723 | 5.82e-15 | 3.76e-13 | 206 |
GO:00356014 | Oral cavity | OSCC | protein deacylation | 74/7305 | 112/18723 | 5.88e-09 | 1.26e-07 | 74 |
GO:00987324 | Oral cavity | OSCC | macromolecule deacylation | 74/7305 | 116/18723 | 5.52e-08 | 1.01e-06 | 74 |
GO:00064764 | Oral cavity | OSCC | protein deacetylation | 66/7305 | 101/18723 | 7.36e-08 | 1.30e-06 | 66 |
GO:00903113 | Oral cavity | OSCC | regulation of protein deacetylation | 30/7305 | 48/18723 | 8.31e-04 | 4.41e-03 | 30 |
GO:00356017 | Thyroid | PTC | protein deacylation | 58/5968 | 112/18723 | 9.29e-06 | 1.05e-04 | 58 |
GO:00064767 | Thyroid | PTC | protein deacetylation | 53/5968 | 101/18723 | 1.36e-05 | 1.47e-04 | 53 |
GO:00070595 | Thyroid | PTC | chromosome segregation | 146/5968 | 346/18723 | 2.99e-05 | 2.87e-04 | 146 |
GO:00987327 | Thyroid | PTC | macromolecule deacylation | 58/5968 | 116/18723 | 3.59e-05 | 3.36e-04 | 58 |
GO:000705913 | Thyroid | ATC | chromosome segregation | 183/6293 | 346/18723 | 8.03e-14 | 4.23e-12 | 183 |
GO:003560114 | Thyroid | ATC | protein deacylation | 61/6293 | 112/18723 | 4.37e-06 | 4.79e-05 | 61 |
GO:000647614 | Thyroid | ATC | protein deacetylation | 56/6293 | 101/18723 | 5.15e-06 | 5.57e-05 | 56 |
GO:009873213 | Thyroid | ATC | macromolecule deacylation | 61/6293 | 116/18723 | 1.89e-05 | 1.72e-04 | 61 |
GO:00903116 | Thyroid | ATC | regulation of protein deacetylation | 25/6293 | 48/18723 | 6.27e-03 | 2.50e-02 | 25 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BEX4 | SNV | Missense_Mutation | rs750282321 | c.157G>A | p.Gly53Arg | p.G53R | Q9NWD9 | protein_coding | tolerated(0.05) | benign(0.03) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
BEX4 | SNV | Missense_Mutation | c.317A>G | p.Gln106Arg | p.Q106R | Q9NWD9 | protein_coding | tolerated(0.85) | benign(0.031) | TCGA-BH-A8G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
BEX4 | SNV | Missense_Mutation | c.71G>T | p.Gly24Val | p.G24V | Q9NWD9 | protein_coding | tolerated(0.28) | benign(0.031) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
BEX4 | SNV | Missense_Mutation | c.125N>G | p.Glu42Gly | p.E42G | Q9NWD9 | protein_coding | deleterious(0.03) | possibly_damaging(0.822) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
BEX4 | SNV | Missense_Mutation | rs749945390 | c.311N>A | p.Arg104His | p.R104H | Q9NWD9 | protein_coding | tolerated(0.06) | possibly_damaging(0.839) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BEX4 | SNV | Missense_Mutation | novel | c.310N>T | p.Arg104Cys | p.R104C | Q9NWD9 | protein_coding | tolerated(0.11) | benign(0.033) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
BEX4 | SNV | Missense_Mutation | rs749945390 | c.311N>A | p.Arg104His | p.R104H | Q9NWD9 | protein_coding | tolerated(0.06) | possibly_damaging(0.839) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
BEX4 | SNV | Missense_Mutation | novel | c.273N>T | p.Lys91Asn | p.K91N | Q9NWD9 | protein_coding | deleterious(0) | benign(0.386) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
BEX4 | SNV | Missense_Mutation | rs761698011 | c.49N>A | p.Ala17Thr | p.A17T | Q9NWD9 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-B5-A5OC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
BEX4 | SNV | Missense_Mutation | novel | c.193G>A | p.Ala65Thr | p.A65T | Q9NWD9 | protein_coding | tolerated(0.13) | possibly_damaging(0.822) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |